Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial
Authors:
- Erica N. GrodinEGErica N. Grodin
- Steven J. NietoSNSteven J. Nieto
- Lindsay R. MeredithLMLindsay R. Meredith
- Elizabeth BurnetteEBElizabeth Burnette
- Edythe D. LondonELEdythe D. London
- Karen MiottoKMKaren Miotto
- Christopher J. EvansCEChristopher J. Evans
- Michael R. IrwinMIMichael R. Irwin
- Lara A. RayLRLara A. Ray
- 11 May 2022
- journal article
- research article
- Published by Wiley in Addiction Biology
- Vol. 27 (4) , e13182
Abstract
Ibudilast, a neuroimmune modulator, shows promise as a pharmacotherapy for alcohol use disorder (AUD). In vivo administration of ibudilast reduces the expression of pro‐inflammatory cytokines in animal models, but its effects on markers of inflammation in humans are unknown. This preliminary study examined the effect of ibudilast on peripheral and potential central markers of inflammation in individuals with AUD. This study also explored the predictive relationship of neurometabolite markers with subsequent drinking in the trial. Non‐treatment‐seeking individuals with an AUD (n = 52) were randomized to receive oral ibudilast (n = 24) or placebo (n = 28) for 2 weeks. Plasma levels of peripheral inflammatory markers were measured at baseline and after 1 and 2 weeks of medication. At study mid‐point, proton magnetic resonance spectroscopy was performed to measure potential neurometabolite markers of inflammation: choline‐compounds (Cho),myo‐inositol (MI) and creatine + phosphocreatine (Cr) in frontal and cingulate cortices from 43 participants (ibudilast:n = 20; placebo:n = 23). The treatment groups were compared on peripheral and central markers. Ibudilast‐treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex. Ibudilast‐treated participants had nominally lower C‐reactive protein levels at visit 2 and nominally lower TNF‐α/IL‐10 ratios, relative to placebo. C‐reactive protein and Cho levels were correlated, controlling for medication. Superior frontal white matter Cho predicted drinking in the following week. Micro‐longitudinal ibudilast treatment may induce peripheral and putative central anti‐inflammatory responses in patients with AUD. The neurometabolite responses may be associated with reduction in drinking, suggesting an anti‐inflammatory component to the therapeutic action of ibudilast.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (F32AA027699, K24AA025704)
- National Institute on Drug Abuse (P50 DA005010‐33)
This publication has 70 references indexed in Scilit:
- Neural activation during processing of aversive faces predicts treatment outcome in alcoholismAddiction Biology, 2013
- Temporal changes in innate immune signals in a rat model of alcohol withdrawal in emotional and cardiorespiratory homeostatic nucleiJournal of Neuroinflammation, 2012
- Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilastProceedings of the National Academy of Sciences, 2010
- Brain Injury and Recovery Following Binge Ethanol: Evidence from In Vivo Magnetic Resonance SpectroscopyBiological Psychiatry, 2010
- Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophagesProceedings of the National Academy of Sciences, 2009
- Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver diseaseAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- In Vivo Evidence for Alcohol-Induced Neurochemical Changes in Rat Brain Without Protracted Withdrawal, Pronounced Thiamine Deficiency, or Severe Liver DamageNeuropsychopharmacology, 2008
- Repeated Lipopolysaccharide (LPS) or Cytokine Treatments Sensitize Ethanol Withdrawal-Induced Anxiety-Like BehaviorNeuropsychopharmacology, 2007
- N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiologyProgress in Neurobiology, 2007
- An anti-inflammatory role for N-acetyl aspartate in stimulated human astroglial cellsBiochemical and Biophysical Research Communications, 2004